WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s Biologics License Application (BLA) for tremelimumab has been accepted for Priority Review in the US, supporting the indication of a single ...

First-line treatment with durvalumab plus tremelimumab and chemotherapy appeared effective for patients with metastatic non-small cell lung cancer, according to randomized phase 3 study results.

In Study 22, the tremelimumab/Imfinzi regimen achieved a median overall survival (OS) of 18.7 months, a finding which AZ’s head of oncology R&D José Baselga said could “change the treatment ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to IMFINZI ® (durvalumab) demonstrated a ...

Patients (n = 1,013) with EGFR/ALK wild-type mNSCLC were randomly assigned (1:1:1) to tremelimumab 75 mg plus durvalumab 1,500 mg and platinum-based chemotherapy for up to four 21-day cycles, followed ...

A total of 332 patients were enrolled (T300 + D, n = 75; durvalumab, n = 104; tremelimumab, n = 69; and T75 + D, n = 84). Tolerability was acceptable across arms, with grade ≥ 3 treatment-related ...

A single priming dose of tremelimumab plus IMFINZI every four weeks reduced risk of death by 22% in HIMALAYA Phase III trial Combination also showed no increase in severe liver toxicity and fewer ...

Tremelimumab was also granted orphan designation in the EU in HCC in 2020. “HIMALAYA is the first Phase III trial to add a novel single priming dose of an anti-CTLA4 antibody to another ...

Please provide your email address to receive an email when new articles are posted on . Durvalumab plus tremelimumab significantly extended OS compared with sorafenib among patients with advanced ...

AstraZeneca's anti-CTLA4 antibody tremelimumab is moving closer to what once looked like an extremely unlikely regulatory approval, after a string of negative trial results. The drugmaker said ...

Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard ...